JP2015519404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519404A5 JP2015519404A5 JP2015517469A JP2015517469A JP2015519404A5 JP 2015519404 A5 JP2015519404 A5 JP 2015519404A5 JP 2015517469 A JP2015517469 A JP 2015517469A JP 2015517469 A JP2015517469 A JP 2015517469A JP 2015519404 A5 JP2015519404 A5 JP 2015519404A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- dnc
- cyclobenzaprine
- composition
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 169
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 151
- 229960003572 cyclobenzaprine Drugs 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 89
- 238000010521 absorption reaction Methods 0.000 claims description 82
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 81
- 229960000836 amitriptyline Drugs 0.000 claims description 81
- 230000036470 plasma concentration Effects 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000002610 basifying agent Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 claims description 3
- 239000002526 disodium citrate Substances 0.000 claims description 3
- 235000019262 disodium citrate Nutrition 0.000 claims description 3
- -1 disodium hydrogen Chemical class 0.000 claims description 3
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical group [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006190 sub-lingual tablet Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 235000015870 tripotassium citrate Nutrition 0.000 claims description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 235000019263 trisodium citrate Nutrition 0.000 claims description 3
- 229940038773 trisodium citrate Drugs 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US61/660,593 | 2012-06-15 | ||
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US61/667,774 | 2012-07-03 | ||
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US61/725,402 | 2012-11-12 | ||
| US201361792900P | 2013-03-15 | 2013-03-15 | |
| US61/792,900 | 2013-03-15 | ||
| PCT/US2013/046023 WO2013188847A1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017192713A Division JP2017222726A (ja) | 2012-06-15 | 2017-10-02 | 経粘膜吸収のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519404A JP2015519404A (ja) | 2015-07-09 |
| JP2015519404A5 true JP2015519404A5 (enExample) | 2016-07-28 |
| JP6259452B2 JP6259452B2 (ja) | 2018-01-10 |
Family
ID=49758769
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517469A Active JP6259452B2 (ja) | 2012-06-15 | 2013-06-14 | 経粘膜吸収のための組成物および方法 |
| JP2017192713A Withdrawn JP2017222726A (ja) | 2012-06-15 | 2017-10-02 | 経粘膜吸収のための組成物および方法 |
| JP2019091262A Withdrawn JP2019123757A (ja) | 2012-06-15 | 2019-05-14 | 経粘膜吸収のための組成物および方法 |
| JP2021100154A Withdrawn JP2021138765A (ja) | 2012-06-15 | 2021-06-16 | 経粘膜吸収のための組成物および方法 |
| JP2024014696A Pending JP2024032964A (ja) | 2012-06-15 | 2024-02-02 | 経粘膜吸収のための組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017192713A Withdrawn JP2017222726A (ja) | 2012-06-15 | 2017-10-02 | 経粘膜吸収のための組成物および方法 |
| JP2019091262A Withdrawn JP2019123757A (ja) | 2012-06-15 | 2019-05-14 | 経粘膜吸収のための組成物および方法 |
| JP2021100154A Withdrawn JP2021138765A (ja) | 2012-06-15 | 2021-06-16 | 経粘膜吸収のための組成物および方法 |
| JP2024014696A Pending JP2024032964A (ja) | 2012-06-15 | 2024-02-02 | 経粘膜吸収のための組成物および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (enExample) |
| EP (1) | EP2861223B1 (enExample) |
| JP (5) | JP6259452B2 (enExample) |
| CN (2) | CN104684550A (enExample) |
| AR (1) | AR092330A1 (enExample) |
| AU (2) | AU2013274003B2 (enExample) |
| BR (1) | BR112014031394B1 (enExample) |
| CA (2) | CA2876902C (enExample) |
| DK (1) | DK2861223T3 (enExample) |
| ES (1) | ES2929133T3 (enExample) |
| HR (1) | HRP20221325T1 (enExample) |
| HU (1) | HUE060175T2 (enExample) |
| IL (1) | IL236268B (enExample) |
| LT (1) | LT2861223T (enExample) |
| MX (2) | MX2021005317A (enExample) |
| MY (1) | MY194495A (enExample) |
| NZ (2) | NZ631144A (enExample) |
| PL (1) | PL2861223T3 (enExample) |
| PT (1) | PT2861223T (enExample) |
| RS (1) | RS63822B1 (enExample) |
| SG (2) | SG10201605407TA (enExample) |
| SI (1) | SI2861223T1 (enExample) |
| SM (1) | SMT202200436T1 (enExample) |
| TW (3) | TWI590820B (enExample) |
| WO (1) | WO2013188847A1 (enExample) |
| ZA (1) | ZA201500288B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| HRP20200055T1 (hr) | 2013-03-15 | 2020-04-03 | Tonix Pharma Holdings Limited | Eutektičke formulacije ciklobenzaprin-klorovodika i manitola |
| JP6614724B2 (ja) * | 2014-09-18 | 2019-12-04 | トニックス ファーマ ホールディングス リミテッド | シクロベンザプリン塩酸塩の共融製剤 |
| US20180207147A1 (en) * | 2015-07-15 | 2018-07-26 | Theranexus | Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo |
| US12337063B2 (en) * | 2016-09-02 | 2025-06-24 | University Of Sharjah | Formulation for atropine sulfate rapidly-disintegrating sublingual tablets |
| CA3069699A1 (en) * | 2017-07-13 | 2019-01-17 | Tonix Pharmaceuticals Holding Corp. | Analogs of cyclobenzaprine and amitryptilene |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| IL275144B2 (en) * | 2017-12-08 | 2024-12-01 | Hoffmann La Roche | Pharmaceutical formulation |
| JP2021505629A (ja) | 2017-12-11 | 2021-02-18 | トニックス ファーマ ホールディングス リミテッド | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| AU2019323764B2 (en) * | 2018-08-20 | 2025-06-05 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
| CA3156118A1 (en) * | 2019-09-30 | 2021-04-08 | Cadila Healthcare Limited | Intranasal pharmaceutical compositions of cyclobenzaprine |
| US20210315841A1 (en) * | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| CN116887830A (zh) * | 2020-11-20 | 2023-10-13 | 通尼克斯医药控股公司 | 酒精使用障碍的环苯扎林治疗 |
| CA3204202A1 (en) | 2020-12-07 | 2022-06-16 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| EP4412602A1 (en) | 2021-10-06 | 2024-08-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| CA3260042A1 (en) | 2022-06-21 | 2023-12-28 | TONIX Pharmaceuticals Holding Corp | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| ES2187156T3 (es) * | 1998-05-14 | 2003-05-16 | Alza Corp | Terapia antidepresiva. |
| ES2192156B1 (es) | 1999-08-13 | 2005-02-16 | Vela Pharmaceuticals, Inc. | Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina. |
| ES2212737B1 (es) | 1999-08-13 | 2005-10-01 | Vela Pharmaceuticals Inc. | Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma. |
| WO2001089476A1 (en) * | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| US7501113B2 (en) * | 2003-02-04 | 2009-03-10 | Philip Morris Usa Inc. | Aerosol formulations and aerosol delivery of buprenorphine |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| HRP20200055T1 (hr) * | 2013-03-15 | 2020-04-03 | Tonix Pharma Holdings Limited | Eutektičke formulacije ciklobenzaprin-klorovodika i manitola |
-
2013
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en active Pending
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en not_active Ceased
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 SM SM20220436T patent/SMT202200436T1/it unknown
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 MX MX2014015436A patent/MX382516B/es unknown
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519404A5 (enExample) | ||
| RU2010121827A (ru) | Композиции для лечения болезни паркинсона | |
| JP6234899B2 (ja) | 喘息及びアレルギー性鼻炎の治療におけるアルギナーゼ阻害剤の使用 | |
| TW200838545A (en) | Therapeutic agent for painful disease | |
| JP2020505407A5 (enExample) | ||
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| JP2017503852A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2009526029A (ja) | （金属含有）殺ウイルス性組成物及び使用 | |
| EA022840B1 (ru) | Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| ES2693779T3 (es) | Ciclesonida para el tratamiento de enfermedades de las vías respiratorias en caballos | |
| JP2016505050A5 (enExample) | ||
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2011500731A5 (enExample) | ||
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| NZ597359A (en) | Emergency interventions of active charcoal with dabigatran etexilate overdosing | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| JP2017513866A5 (enExample) | ||
| JP2020525451A5 (enExample) |